Sugi Predict

Sugi Predict / Compounds / SCHEMBL444147

SCHEMBL444147

SCHEMBL444147

COc1ccc2c(c1)C[N]CC2

nearest known ligand 0.50

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ DRD2 P14416 7/20 0.47
▸ DRD3 P35462 7/20 0.47
▸ DRD1 P21728 7/20 0.46
▸ DRD5 P21918 7/20 0.46
▸ DRD4 P21917 4/20 0.45
▸ BCL2 P10415 1/20 0.44
▸ CHRNA7 P36544 1/20 0.44
▸ ADRA2A P08913 1/20 0.42
▸ HTR5A P47898 1/20 0.41
▸ CYP19A1 P11511 1/20 0.41
▸ METAP1 P53582 1/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL446529 0.93 DRD1 (0.50) DRD2DRD3DRD1DRD5DRD4
SCHEMBL1550649 0.89 DRD1 (0.53) DRD2DRD3DRD1DRD5DRD4
SCHEMBL586334 0.84 DRD2 (0.47) DRD2DRD3DRD1DRD5DRD4
SCHEMBL8419347 0.82 DRD1 (0.48) DRD2DRD3DRD1DRD5DRD4
SCHEMBL2607471 0.78 DRD1 (0.62) DRD2DRD3DRD1DRD5DRD4
SCHEMBL443555 0.75 MAOA (0.50) CHRNA7KDM4EALDH1A1MAPT
SCHEMBL1506557 0.74 DRD1 (0.62) DRD2DRD3DRD1DRD5DRD4
SCHEMBL30299229 0.74 DRD1 (0.62) DRD2DRD3DRD1DRD5DRD4
SCHEMBL577378 0.74 DRD1 (0.62) DRD2DRD3DRD1DRD5DRD4
SCHEMBL31028084 0.74 DRD1 (0.62) DRD2DRD3DRD1DRD5DRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3363788-A1 CANNABINOID RECEPTOR MODULATORS Arena Pharmaceuticals, Inc. (US) 2018-08-22 — — EP claimed
US-20130165412-A1 CANNABINOID RECEPTOR MODULATORS ARENA PHARMACEUTICALS, INC. 2013-06-27 — — US claimed
US-20120214766-A1 CANNABINOID RECEPTOR MODULATORS ARENA PHARMACEUTICALS, INC. 2012-08-23 — — US claimed
EP-2470508-A1 CANNABINOID RECEPTOR MODULATORS Arena Pharmaceuticals, Inc. (US) 2012-07-04 — — EP claimed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 — — US claimed
EP-2382012-A2 PHARMACEUTICAL COMPOUNDS Bial-Portela & CA, S.A. (PT) 2011-11-02 — — EP claimed
WO-2011025541-A1 CANNABINOID RECEPTOR MODULATORS ARENA PHARMACEUTICALS, INC. (US) 2011-03-03 — — WO claimed
WO-2010074588-A2 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2010-07-01 — — WO claimed
WO-2010022055-A2 INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS AMGEN INC. (US) 2010-02-25 — — WO claimed
WO-2009023669-A1 SUBSTITUTED 5,6,7,8-TETRAHYDROQUINOLINE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE THEREOF JANSSEN PHARMACEUTICA N.V. (BE) 2009-02-19 — — WO claimed
US-20090048295-A1 SUBSTITUTED 5,6,7,8-TETRAHYDROQUINOLINE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE THEREOF JANSSEN PHARMACEUTICE N.V. (BE) 2009-02-19 — — US claimed
US-11771695-B2 Cannabinoid receptor modulators ARENA PHARMACEUTICALS, INC. (US) 2023-10-03 — — US disclosed
US-11746091-B2 Cannabinoid receptor modulators ARENA PHARMACEUTICALS, INC. (US) 2023-09-05 — — US disclosed
US-20220241274-A1 CANNABINOID RECEPTOR MODULATORS ARENA PHARMACEUTICALS, INC. 2022-08-04 — — US disclosed
CN-109970708-B Cannabinoid receptor modulators 艾尼纳制药公司 2022-06-21 — — CN disclosed
WO-2010022055-A2 INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS AMGEN INC. (US) 2010-02-25 — — WO disclosed
WO-2009023669-A1 SUBSTITUTED 5,6,7,8-TETRAHYDROQUINOLINE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE THEREOF JANSSEN PHARMACEUTICA N.V. (BE) 2009-02-19 — — WO disclosed
US-20090048295-A1 SUBSTITUTED 5,6,7,8-TETRAHYDROQUINOLINE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE THEREOF JANSSEN PHARMACEUTICE N.V. (BE) 2009-02-19 — — US disclosed
US-5618814-A Trisubstituted pyrimido [5,4-d] pyrimidines for modulating multi-drug resistance and pharmaceutical compositions containing these compounds DR. KARL THOMAE GMBH (DE) 1997-04-08 — — US disclosed
EP-0645390-A1 Trisubstituted pyrimido 5,4-d pyrimidines for modulating multidrug resistance, drugs containing these compounds and processes for their preparation Dr. Karl Thomae GmbH (DE) 1995-03-29 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120214766-A1 CANNABINOID RECEPTOR MODULATORS CNR1, CNR2, TRPV1 DRD2 1476/4885DRD3 1764/4885DRD1 1465/4885
US-20090048295-A1 SUBSTITUTED 5,6,7,8-TETRAHYDROQUINOLINE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE THEREOF C3AR1, C5AR1, C5AR2 DRD2 2097/4885DRD3 2577/4885DRD1 3935/4885
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS FAAH, FAAH2, ASAH1 DRD2 1602/4885DRD3 1627/4885DRD1 1830/4885
US-11746091-B2 Cannabinoid receptor modulators CNR1, CNR2, TRPV1 DRD2 1476/4885DRD3 1764/4885DRD1 1465/4885
US-20220241274-A1 CANNABINOID RECEPTOR MODULATORS CNR2, CNR1, OPRL1 DRD2 669/4885DRD3 859/4885DRD1 1041/4885
US-11771695-B2 Cannabinoid receptor modulators CNR2, CNR1, OPRL1 DRD2 669/4885DRD3 859/4885DRD1 1041/4885
US-20130165412-A1 CANNABINOID RECEPTOR MODULATORS CNR1, CNR2, TRPV1 DRD2 1476/4885DRD3 1764/4885DRD1 1465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.